Auris Medical Holding Ltd. (NASDAQ: EARS) Chooses Colorectal Cancer as the first Indication For OlogoPhore Platform

Auris Medical Holding Ltd. (NASDAQ: EARS) has announced that mutant KRAS-driven colorectal cancer has been chosen as the first therapeutic indication for the company‚Äôs OligoPhore oligonucleotide delivery platform. The treatment will be developed under project code AM-401, with an IND filing planned by the end of 2022. CRC among leading […]